- NanaBis is completely built on the NanoCelle delivery platform, which is the key differentiator over every other cannabinoid product or company seeking regulatory approvals globally.
- Validating NanoCelle through an FDA approved drug (NanaBis) literally *is* their core business and a major way they will generate huge concrete revenues through immediate sales and lock down big pharma partnerships on NanoCelle.
- Based on precedents such as GW Pharma's Epidiolex, or even Sativex (which I suspect was the drug NanaBis has already blown out of the water in independent testing) an FDA approval will be immensely profitable (~US$500m+ YR1 sales).
If anything, by divesting the VMS business, cutting costs and locking down funds through a Nasdaq listing, Medlab seem to be extremely focussed on their core business objectives.
- Forums
- ASX - By Stock
- MDC
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-27
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MDC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$6.60 |
Change
0.000(0.00%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
MDC (ASX) Chart |
Day chart unavailable